Archives: Agenda

• Defining clear roles and responsibilities between sponsor and CRO to avoid duplication and gaps
• Identifying what sponsors should actively oversee versus what can be delegated with confidence
• Setting meaningful KPIs and oversight models that focus on risk rather than excessive monitoring
• Improving communication and escalation pathways to prevent delays and misalignment
• Avoiding common mistakes that lead to over-control increased workload and inefficiencies

• Comparing timelines and setup across the UK EU and other key regions
• Understanding trade-offs between speed cost quality and patient access
• Deciding how to prioritise regions based on trial type and strategy

1 x Biopharma panel seat available

1 x Vendor panel seat available